CLINICAL BENEFIT OF ADALIMUMAB DOSE ADJUSTMENT FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE IN EXTEND

Jean-Frederic Colombel  ¹     Paul Rutgeerts  ²     William Sandborn  ³     Douglas C. Wolf  ⁴     Walter Reinisch  ⁵     Gert Van Assche  ²     Samantha Eichner  ⁶     Joel Petersson  ⁷     Anne M. Robinson     Roopal B Thakkar    
¹ Icahn School Of Medicine At Mount Sinai, New York, United States
² University Of Leuven, Leuven, Belgium
³ Ucsd, La Jolla, United States
⁴ Atlanta Gastroenterology Associates, Atlanta, United States
⁵ Mcmaster University, Hamilton, Canada
⁶ Abbvie Inc, North Chicago, United States
⁷ Abbvie Inc, North

Conference
UEG Week 2014

Citation
United European Gastroenterology Journal; 2014: 2 (Supplement 1)